High costs of orphan drugs: Patients pay the price for policy hurdles in India

India manufactures APIs for over 400 FDA-approved orphan drugs, but patients face high costs due to Indian pharma companies' reluctance to develop these drugs domestically.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yp4mG8g
via IFTTT